Biomedical Engineering Reference
In-Depth Information
[49] Macadam A. The effect of gastro-intestinal mucus on drug absorption. Adv Drug Deliv
Rev 1993;11:201-20.
[50] Schachter H, Williams D. Biosynthesis of mucus glycoproteins. In: Chantler ENJ,
Elden B, Elstein M, editors. Advances in experimental medicine and biology, vol. 144.
New York, NY: Plenum Press; 1982. p. 3-28.
[51] Allen A, Garner A. Mucus and bicarbonate secretion in the stomach and their possible
role in mucosal protection. Gut 1980;21:249-62.
[52] Kompella UB, Vincent HLLee. Delivery systems for penetration enhancement of peptide
and protein drugs: design considerations. Adv Drug Deliv Rev 1992;46:115-62.
[53] Vincent HLLee, Yamamoto A. Penetration and enzymatic barriers to peptide and protein
absorption. Adv Drug Deliv Rev 1989;4:171-207.
[54] Langguth P, Bohner V, Heizmann J, Merkle HP, Wolffram S, Amidon GL, et al. The challenge
of proteolytic enzymes in intestinal peptide delivery. J Control Release 1997;46:39-57.
[55] Ganong WF. Regulation of gastrointestinal function. In: Ganong WF, editor. Review of medi-
cal physiology. 12th ed. Los Altos, CA: Lange Medical Publications; 1983. p. 394-420.
[56] Mrsny RJ. Challenges for the oral delivery of proteins and peptidesPeptides: theoretical
and practical approaches to their delivery. Greenwood, SC: Capsugel Symposia Series;
1991. p. 45-52.
[57] Woodley J. Enzymatic barriers. In: Bernkop-Schnurch A, editor. Oral delivery of macro-
molecular drugs. New York, NY: Springer Science and Business Media; 2009. p. 1-19.
[58] Vazeux G, Iturrioz X, Corvol P, Llorens-Cortes C. A glutamate residue contributes to the
exopeptidase specificity in aminopeptidase A. Biochem J 1998;334:407-13.
[59] Bai JP, Amidon GL. Structural specificity of mucosal-cell transport and metabolism of
peptide drugs: implication for oral peptide drug delivery. Pharm Res 1992;9:969-78.
[60] Vincent HL Lee. Enzymatic barriers to peptide and protein absorption. Crit Rev Ther
Drug Carrier Syst 1988;5:68-97.
[61] Lee HLV, Dodda-Kashi S, Grass GM, Rubas W. Oral route of peptide and protein drug
delivery. In: Lee HLV, editor. Peptide and protein drug delivery. New York, NY: Marcel
Dekker; 1991. p. 691-738.
[62] Wearley LL. Recent progress in protein and peptide delivery by noninvasive routes. Crit
Rev Ther Drug Carrier Syst 1991;8:331-94.
[63] Sasaki I, Fujita T, Murakami M, Yamamoto A, Nakamura E, Imasaki H, et al. Intestinal
absorption of azetirelin, a new thyrotropin-releasing hormone (TRH) analogue. I. Possible
factors for the low oral bioavailability in rats. Biol Pharm Bull 1994;17:1256-61.
[64] Hayakawa E, Lee HLV. Aminopeptidase activity in the jejunal and ileal Peyer's patches
of the albino rabbit. Pharm Res 1992;9:535-40.
[65] Wang W. Oral protein drug delivery. J Drug Target 1996;4:195-232.
[66] Mrsny RJ, Cromwell M, Villagran J, Rubas W. Oral delivery of peptides to the small
intestineCurrent status on targeted drug delivery to the gastrointestinal tract. Greenwood,
SC: Capsugel Symposia Series; 1993. p. 45-56.
[67] Mahato RI, Narang AS, Thoma L, Miller DD. Emerging trends in oral delivery of peptide
and protein drugs. Crit Rev Ther Drug Carrier Syst 2003;20:153-214.
[68] Fasano A. Novel approaches for oral delivery of macromolecules. J Pharm Sci 1998;
87:1351-6.
[69] Ward PD, Tippin TK, Thakker DR. Enhancing paracellular permeability by modulating
epithelial tight junctions. Pharm Sci Technol Today 2000;3:346-58.
[70] Salamat-Miller N, Johnston TP. Current strategies used to enhance the paracellu-
lar transport of therapeutic polypeptides across the intestinal epithelium. Int J Pharm
2005;294:201-16.
Search WWH ::




Custom Search